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open acA B S T R A C T
Objectives: Three hundred million people living with rare diseases worldwide are disproportionately deprived of in-time
diagnosis and treatment compared with other patients. This review provides an overview of global policies that optimize
development, licensing, pricing, and reimbursement of orphan drugs.
Methods: Pharmaceutical legislation and policies related to access and regulation of orphan drugs were examined from 194
World Health Organization member countries and 6 areas. Orphan drug policies (ODPs) were identified through internet
search, emails to national pharmacovigilance centers, and systematic academic literature search. Texts from selected pub-
lications were extracted for content analysis.
Results: One hundred seventy-two drug regulation documents and 77 academic publications from 162 countries/areas were
included. Ninety-two of 200 countries/areas (46.0%) had documentation on ODPs. Thirty-four subthemes from content
analysis were categorized into 6 policy themes, namely, orphan drug designation, marketing authorization, safety and
efficacy requirements, price regulation, incentives that encourage market availability, and incentives that encourage
research and development. Countries/areas with ODPs were statistically wealthier (gross national income per capita =
$10 875 vs $3950, P , .001). Country/area income was also positively correlated with the scope of the respective ODP
(correlation coefficient = 0.57, P , .001).
Conclusions: Globally, the number of countries with an ODP has grown rapidly since 2013. Nevertheless, disparities in
geographical distribution and income levels affect the establishment of ODPs. Furthermore, identified policy gaps in price
regulation, incentives that encourage market availability, and incentives that encourage research and development should be
addressed to improve access to available and affordable orphan drugs.
Keywords: drug regulatory, health equity, orphan drug policy, rare diseases, treatment access.
VALUE HEALTH. 2020; 23(12):1580–1591likely to die by age 5.4 With over 7000 types identified worldwide,Introduction
An orphan drug can be defined as any medicinal product
intended for a rare disease or a disease with no existing satisfac-
tory method of diagnosis, prevention, or treatment.1,2 Accounting
for the varying terminologies and definitions across nations and
organizations, rare diseases are typically defined as conditions
with limited treatment alternatives, with an average prevalence of
fewer than 40 to 50 cases per 100 000 population or that affect a
small number of patients compared with the total population.3
Although individually rare, these diseases collectively affect 300
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HEALTH POLICY ANALYSIS 1581of patients with rare diseases. The Orphan Drug Act, enacted by
the Food and Drug Administration (FDA) of the United States in
1983, was the first legislation to regulate orphan drugs and offered
financial and regulatory incentives to companies that developed
and registered orphan drugs.8 From 1983 to 2009, over 2000
orphan drug applications were submitted to the FDA, with the
approval of approximately 350 orphan drugs for over 420 in-
dications compared to only 34 drugs eligible for approval between
1967 and 1983.9,10 Since then, more authorities have set up orphan
drug legislation for their jurisdictions, including the European
Union, Singapore, Japan, Australia, South Korea, and Taiwan. In
recent years, increasing numbers of non-high-income countries
have included orphan drug policy (ODP) development in their
policy agenda.11
Several articles reviewed country-specific orphan drug and
rare disease policies, which were limited by the scope of selected
countries or were restricted to English peer-reviewed journal ar-
ticles.11-13 Current development of ODP on a global scale remains
unclear for several reasons. Firstly, most policy documents were
published through governmental channels and were not reported
in journal articles. Secondly, these documents may not be elec-
tronically accessible to the public. Thirdly, ODP may not be avail-
able as a separate document but could be embedded within a
wider piece of legislation, making it difficult for academic search
engines to identify. Finally, these documents are likely to be
written in the local language of the countries/areas of interest.
This study aims to provide an up-to-date global overview of ODP
in the era of innovative medicine and to reflect associated changes
in drug regulation policy.Methods
Establishment and scope of ODP were examined from 194
World Health Organization (WHO) member countries and 6
nonmember areas (Hong Kong, Kosovo, Macau, Palestine, Sahrawi
Republic, and Taiwan) with independent drug regulatory author-
ities.14 An ODP is defined as any “formal decision or a plan of
action that has been taken by, or has involved, a state organisa-
tion”15 related to the access and regulation of orphan drugs, in the
form of pharmaceutical legislation, regulation, or policies. Other
terminologies, including “access,”16,17 “availability,”16 “reim-
bursement,”18 “marketing authorization,”19 and “regulation,” used
in this review, are defined in Table 1.
Government Information Source
Governmental policy documents on drug regulation were
searched, reviewed, and retrieved through (1) a standardized
internet search by keywords (see Appendix 1 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2020.06.020), (2)
scanning websites of drug regulatory authorities (DRAs) of each
country/area, and (3) direct emails toDRAs toverify the information
from the internet. Emails were sent to national pharmacovigilance
centersparticipating in theWHOProgramme for InternationalDrug
Monitoring, assisted by the program coordinating office at WHO
headquarters and the network of the International Society of
Pharmacovigilance, to confirm the latest country-specific ODP sta-
tus and to request official documents mentioning existing ODP that
were not publicly accessible at the time of this study. Policy docu-
ment collection ended on July 31, 2019.
Academic Information Source
A systematic review of academic literature was performed to
ensure comprehensive reporting and to complement theinformation from government documentation. Searched data-
bases include PubMed, EMBASE, Web of Science, and the Cochrane
Library. The academic literature was searched following the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines and updated to July 31, 2019.20 The search
strategy include the keywords (“orphan” or “high cost” or “rare
diseases”) and (“drugs” or “medicines” or “pharmaceuticals”) and
(“legislation” or “regulation” or “policy”) in any field (see Ap-
pendix 1 in Supplemental Materials found at https://doi.org/10.1
016/j.jval.2020.06.020). An additional manual search was con-
ducted based on the reference lists of included articles.
Eligibility Criteria and Publication Selection
All government documentation that described any policies,
legislation, or regulation related to orphan medicine and drugs
developed to diagnose, prevent, or treat rare diseases was
screened and selected. Policies implemented by nongovernmental
entities were excluded. For academic literature, all peer-reviewed
drug policy research, including systematic reviews, comparative
analyses, policy analyses, and original studies with mixed
methods that focused on ODP, were included. Reference lists of
included studies were searched and reviewed manually with
additional literature added. All government documents and aca-
demic articles were screened, selected, reviewed, and cross-
checked independently. Discrepancies in publication selection
were settled during consensus meetings.
Data Extraction
Information on the establishment of the DRA (existence, name,
and website) and status of ODP for each country/area was
extracted from included documentation and publications. Coun-
try/area names and geographical areas were documented ac-
cording to the WHO member country list.14 Country/area income
(gross national income per capita) and income level (high income,
upper-middle income, lower-middle income, and low income)
were documented according to the World Bank Report in
2019.21,22 Absence of ODP was confirmed if no evidence was found
after thorough perusal of regulation documents and academic
literature. Orphan drug policy establishment was determined as
unknown if the country’s drug regulation documents were not
available from the DRA website, internet search, email corre-
spondence, or academic literature. Non-English documents were
translated into English for data extraction and analyses.
Data Synthesis and Content Analysis
Themes and subthemes of orphan drug policy were pre-
identified based on 2 previous studies (see Appendix 2 in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2020.
06.020).11,23 Relevant texts from included documents and publi-
cations were extracted and categorized accordingly by A.Y.L.C.
Additional themes/subthemes were generated for texts that could
not be categorized under the preidentified themes/subthemes.
V.K.Y.C. and M.G. crosschecked the data extraction spreadsheet
and categorization by reviewing each governmental publication
and academic publication, respectively. Consensus meetings were
held with A.Y.L.C., V.K.Y.C., M.G., and senior author X.L. to confirm
theme and subtheme categorization.
Statistical Analysis and Data Visualization
The scope of the established ODP was calculated using the
percentage of subthemes addressed in the policy documents of
each country/area over the total number of subthemes identified
globally. A heat map was used to illustrate the level of ODP
Table 1. Definitions of terminologies.
Terms Definitions
Access Ability or potential to receive appropriate treatment, if needed, to achieve best possible
outcome. It is measured in physical accessibility, affordability, and acceptability, but not
merely the adequate supply of treatment.
Availability Adequacy of supply for required treatment or presence of policy
Reimbursement Rational decision and amount that payers are willing to pay and cover services and
medications on behalf of end users
Marketing authorization Issuance of approval status by a competent drug regulatory authority for marketing or
free product distribution after comprehensive scientific evaluation
Regulation Policy set by a statutory body to exert control in accordance with higher legislative
framework
1582 VALUE IN HEALTH DECEMBER 2020development. The income difference between countries/areas
with and without an established ODP was tested using the
Mann-Whitney U Test. The correlation between country incomes
and the scope of ODP subthemes was analyzed using the
Spearman correlation. We used R Foundation for Statistical
Computing version 3.6.0 (Vienna, Austria) and ggplot2 for data
analysis and visualization.Results
Evidence From Government Documents and Academic
Literature
A total of 172 drug regulation documents from 162 of the 200
countries/areas were found and read in full (see Appendix 3 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.202
0.06.020). The remaining 38 countries had no identifiable drug
regulation documents owing to a lack of an identifiable DRA (n =
7), a lack of identifiable DRA websites (n = 9), inaccessible DRA
websites (n = 4), or DRA websites without identifiable drug
regulation documents (n = 18).
A total of 77 academic publications were included in our
narrative synthesis based on eligibility criteria (see Appendix 4 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.202
0.06.020). Of the 68 countries/areas discussed in academic litera-
ture, 42 were reported to have an existing ODP while 26 had no
identifiedODPdespite reporting significantunmetneeds.Academic
interest inODP is growing globally over theyears (seeAppendix5 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.202
0.06.020). Although the Orphan Drug Act was established in 1983,
only 6 countries had made contributions to the academic literature
concerning ODP until 2000. Following the establishment of the EU
Orphan Medicine Regulation in 2000, discussions around ODP
surged between 2006 and 2010, and 2014 and 2018, respectively.
Establishment of ODP by Country
Orphan drug policies were identified under a range of
descriptive terms for statutory or regulatory instruments such as
acts, decrees, guidelines, ordinances, or policies, each corre-
sponding to the respective countries’/areas’ legal structures,
enforced by DRAs. We identified 92 countries/areas (92/200,
46.0%) with legislation, regulations, or policies that facilitated
patient access to orphan drugs (Fig. 1). Europe was identified as
having the highest ODP establishment rate (42 of 54, 77.8%), with
Africa having the lowest (6 of 47, 12.8%).
Between 2013 and2019, ODP establishment increased gradually
in non-high-income countries/areas (Fig. 2). Of the 37 countries/
areaswith an establishedODP since 2013, 20 (54.1%)were of low- orlower-middle-income, and 10 (27.0%) were of upper-middle in-
come.Nonetheless, at the timeof this study, countries/areaswith an
ODPwere statisticallywealthier (gross national incomeper capita =
$10875 vs $3950, P, .001). Orphan drug policies were established
in only 19.4% of the 31 low-income countries/areas; indicating a
considerable policy gap in these countries/areas.
Characteristics of Global ODP
Content analysis of extracted texts from governmental and
academic sources yielded 34 subthemes, which were categorized
into 6 themes, namely, orphan drug designation, marketing
authorization, safety and efficacy requirements, price regulation,
incentives that encourage market availability, and incentives that
encourage research and development (Table 2). Themes and
subthemes of ODP by country/area are summarized in Table 2 and
in Appendix 6 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2020.06.020. The number of countries/areas
with policy themes are presented with quotes to illustrate each
theme in Table 3. High-income countries comprised a greater
proportion with an established ODP and a broader scope of ODP
themes/subthemes (Fig. 3). Spearman correlation showed that
country/area income was positively correlated with policy scope
(correlation coefficient = 0.57, P , .001).
Identified Themes in ODP
Orphan drug designation was the most frequent theme iden-
tified. This refers to the special status granted by a DRA that
qualifies a medicinal product for exclusive development and
marketing conditions. Orphan drugs are often defined as drugs
intended for the treatment, diagnosis, prophylaxis, or rehabilita-
tion of rare diseases. When defining rare diseases, most countries/
areas adhered to the European Union definition of low prevalence
(0.05%), whereas others followed the number of prevalent cases,
such as Australia (,2000), South Korea (,20 000), and the United
States (,200 000). Countries/areas such as Chile, Kenya, Peru, and
Singapore required the disease severity to be “life threatening”
and “‘severely-’ or ‘chronically-’ debilitating.” Orphan drugs are
also defined by their availability as pharmaceutical products or
active ingredients not developed, imported, or registered owing to
low commercial returns and unfavorable marketing conditions.
Countries/areas such as China and Vietnam acknowledged orphan
drug designation from referenced competent authorities.
Marketing authorization refers to the marketing permit or li-
cense granted for an orphan drug before importation or supply in
the form of samples (paid or free), wholesale, or retail. The validity
of such permits range from 12 months to 5 years. Thirteen
countries/areas exempted orphan drugs from drug registration on
essential medicines lists, drug registries, product licences, or serial
Figure 1. Geographical distribution of orphan drug policy establishment.
Figure 2. Cumulative percentage of countries with an established orphan drug policy, by income level.
HIC indicates high-income countries; LIC, low-income countries; LMIC, lower-middle income countries; UMIC, upper-middle-income countries.
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Table 2. Themes and subthemes of orphan drug policy in the content analysis.
Theme Subtheme
Orphan drug designation Definition of rare diseases
Designation or official list of rare diseases
Definition of orphan drugs
Designation or official list of orphan drugs
Criteria and procedures for orphan drug designation
Designation committee
Marketing authorization Provisions for marketing authorization
Criteria for obtaining marketing authorization
Validity duration of marketing authorization
Priority/expedited/accelerated/fast-track approval
Reference to overseas orphan drug approval
Premarketing authorization access
Safety and efficacy requirements Proof of efficacy/safety/cost-effectiveness
Clinical trial authorization/exemption
Health technology assessment criteria
Definition/requirements of sponsor or applicant
Pharmacovigilance requirement/adverse event monitoring
Recall of products
Price regulation Provisions and guidelines for price regulation
Mode of price regulation
Managed entry agreements
Exemption from price regulation
Maximum retail price
Incentives that encourage market availability Payer subsidies/reimbursement/funding/copayment
Financial assistance for cross-border health access
Compassionate use
Tax credits or exemptions
Fee refund/reduction/waiver
Sponsor/applicant reimbursement
Incentives that encourage research and development Patent protection/market exclusivity/monopolization
Funding for research/development/clinical trials
Protocol assistance
Scientific advice/consultation
National plan or strategy
1584 VALUE IN HEALTH DECEMBER 2020and quality control. Forty-three countries/areas had provision for
priority review, expedited registration, or fast-track approval for
orphan drugs. Timelines for authorization decisions ranged from 5
days to 12 months. The fastest approval time was identified in
Costa Rica (5 days), followed by Chile and the United Arab Emir-
ates (both 20 days). In countries such as Kazakhstan and Panama,
fast-track approval was identified without a specified timeline.
Owing to limited uptake, comprehensive proof of quality,
safety, and efficacy of candidate orphan drugs may not be readily
available. To ensure high regulatory standards, drug regulations in
Kazakhstan require applicants to conduct a specific study program
whereby findings form the basis for benefit-risk ratio evaluation.
In Brazil, where complete clinical development of orphan drugs is
not available, clinical reports containing efficacy data based on
Brazilian or international references, in vivo and in vitro studies, or
relative bioequivalence studies using international comparatormedicines are accepted as proof of efficacy. Risk minimization
plans, pharmacovigilance plans, and updated reports of the
orphan drug from drug commercialized countries were consid-
ered acceptable proof of safety.
To mitigate steep costs and low commercial interests, some
countries/areas provide incentives to encourage orphan drug
research and development. In the United States, clinical research
that evaluated the safety and efficacy of orphan drugs was funded
through the Orphan Products Clinical Trials Grants Programme by
the FDA and the Orphan Products Research Project Grant by the
National Institutes of Health. Patent protection in the form of
market exclusivity was provided for each orphan drug with
duration ranging from 5 years (Australia), 7 years (United States),
8 years, or 8.5 years for pediatric orphan drugs (Canada) to 10
years (European Union, Japan, Taiwan). Provision for scientific
advice or consultation concerning the design and implementation
Table 3. Summary of orphan drug policy themes coverage.
Themes (number of
countries/areas)
Quotations to illustrate the themes
Orphan drug designation (82 of
92, 89.1%)
Definition of rare diseases:
“‘rare disease or condition’ means any disease or condition which (A) affects less than 200,000 persons
in the United States, or (B) affects more than 200,000 in the United States and for which there is no
reasonable expectation that the cost of developing and making available in the United States a drug for
such disease or condition will recovered from sales in the United States of such drug.” (United States)
Designation of rare diseases:
“The DOH, upon recommendation of the RDTWG, shall have the authority to designate any disease that
is recognized to rarely afflict the population of the country as a rare disease.” (The Philippines)
Criteria and procedures for orphan drug designation:
“Article 3 Criteria for designation
1. A medicinal product shall be designated as an orphan medicinal product if its sponsor can establish:
(a) that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically
debilitating condition affecting not more than five in 10 thousand persons in the Community when the
application is made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening,
seriously debilitating or serious and chronic condition in the Community and that without incentives it is
unlikely that the marketing of the medicinal product in the Community would generate sufficient return
to justify the necessary investment; and (b) that there exists no satisfactory method of diagnosis,
prevention or treatment of the condition in question that has been authorized in the Community or, if
such method exists, that the medicinal product will be of significant benefit to those affected by that
condition .
Article 5 Procedure for designation and removal from the register
1. “In order to obtain the designation of a medicinal product as an orphan medicinal product, the
sponsor shall submit an application to the Agency at any stage of the development of the medicinal
product before the application for marketing authorization is made .” (European Union)
Marketing authorization (78 of 92,
84.8%)
Provisions for marketing authorization:
“Pharmaceutical products intended both for the Kenya market as well as products intended for export
will be registered with the Pharmacy and Poisons Board. The following criteria will be used in the
registration: .
(4) Unique characteristic of the drug product such as life-saving and orphan drugs. Orphan drugs are
products for rare conditions for which the small size of the local market would make registration
otherwise commercially unattractive.” (Kenya)
Validity duration of marketing authorization:
“The retention of the listed product in the register of listed products will be for a duration of 12 (twelve)
months and is renewable subject to review at the end of the retention period.” (Sierra Leone)
Priority/expedited/accelerated/fast-track approval:
“Applications under this category shall have a decision made within three (3) months of submission.”
(Ghana)
Reference to overseas orphan drug approval:
“to prioritize the registration for circulation and grant of import permits for rare drugs and vaccines
which have been assessed for prequalification by the World Health Organization” (Vietnam)
Pre marketing authorization access:
“A Marketing Authorization shall not be required for, as follows: 5.1. a magistral preparation and a
galenic product; 5.2. an orphan medicinal product; .” (Kosovo)
Safety and efficacy requirements
(44 of 92, 47.8%)
Clinical trial authorization/exemption
“CDSCO may relax such requirement of local Phase IV clinical trial, where the new drug is indicated in
life threatening or serious diseases or diseases of special relevance to Indian health scenario or for a
condition which is unmet need in India such as XDR tuberculosis, hepatitis C, H1N1, dengue, malaria,
HIV, or for the rare diseases for which drugs are not available or available at a high cost or if it is an
orphan drug.” (India)
Health technology assessment criteria
“We only consider drugs for very rare conditions. The majority of our topics are identified by the
National Institute for Health Research Innovation Observatory. They aim to notify the Department of
Health and Social Care of key, new and emerging healthcare technologies that might need to be
referred to NICE against the following timeframes:
new drugs, in development, at 20 months to marketing authorisation
new indications, at 15 months to marketing authorisation.” (United Kingdom)
Definition/requirements of sponsor or applicant:
“Positive decision on state registration of orphan drugs can be made if the Applicant assumes obligation
to:
(1) carry out a specific study program within a specified time period, the results of which will be the basis
for re-evaluation of the ‘benefit-risk’ ratio; (2) to ensure application of the medicinal drug under strict
medical supervision; (3) immediately inform the governmental body of any adverse effects emerging
due to the orphan drug application and measures taken.” (Kazakhstan)
continued on next page




Quotations to illustrate the themes
Pharmacovigilance requirement/adverse event monitoring:
“. surveillance activities and monitoring of quality, safety, and efficacy will be
implemented within six months after the product is registered. Surveillance
procedures and requirements are as follows:
a) The product registration holder must report any adverse reactions involving
orphan product to NPRA (.)
b) Periodic Safety Updates Report (PSUR)/Periodic Benefit Risk Evaluation Report
(PBRER) must be submitted to NPRA for orphan products in the category of new
chemical entities/new products and biologics every 6 months for the first 2 years
and once a year for the following 3 years.
c) Products will be sampled and tested to ensure that it complies to the established
standards and specifications. Actions will be taken against products that do not
comply to the established standards.” (Malaysia)
Price regulation (21 of 92, 22.8%) Mode of price regulation:
“The Economic Committee for Health Products of the Ministry of Health negotiates
the price of an orphan drug with the pharmaceutical company, taking into account
the improvement in clinical added value of the drug; prices of drugs serving the
same therapeutic purpose; sales volumes; conditions of use; and prices in Ireland,
Italy, Portugal, Spain and the European Union. The Ministry of Health decides on
reimbursement taking into account the clinical added value of the drug and the
improvement in the clinical added value of the drug as compared to existing
therapies.” (France)
Managed entry agreements
“After a negative advice, companies may enter into negotiations for managed
entry agreements (in which for example, the pharmaceutical company refunds
a predefined percentage of the price for every unit sold) as defined by the Royal
Decree of December 21th, 2001” (Belgium)
Exemption from price regulation
“(5) Maximum increase on hardship cases (except for orphan drugs, lower priced
drugs & intravenous infusions) shall be 8% per annum of the existing approved
MRPof the respective drug. In case of lower priced drugs, increase shall not
exceed 25 paisa per tablet/capsule/respule/caplet/patch/5ml of syrup, suspension
and elixir.” (Pakistan)
Maximum retail price
“Zur Wahrung des finanziellen Gleichgewichts des Systems der sozialen Sicherheit
darf einem ozialversicherungsträger für eine Arzneispezialität dieses Bereiches
höchstens der ermittelte EU-Durchschnittspreis verrechnet werden.” (Austria)
Incentives that encourage
market availability (43 of 92,
46.7%)
Financial assistance for cross-border health access
“Rare disease patients or their legal guardians may apply to the central
competent authority by submitting an application form, together with certificates,
care plans and relevant documents issued by a medical care or research institution
specified in Article 10; after review and approval by the Review Committee, the
central competent authority may provide subsidies for patients to travel overseas
and participate in international medical cooperation projects.” (Taiwan)
Tax credits or exemptions
“SEC. 44H. CLINICAL TESTING EXPENSES FOR CERTAIN DRUGS FOR RARE DISEASES
OR CONDITIONS. (a) GENERAL RULE.-There shall be allowed as a credit against
the tax imposed by this chapter for the taxable year an amount equal to 50
percent of the qualified clinical testing expenses for the taxable year.”
(United States)
Fee refund/reduction/waiver
“The Secretary must waive the following fees: (a) a fee that would have been payable,
but for this subregulation, as part of an application under subsection 22C(1) of the
Act relating to a medicine that is a designated orphan drug; (b) a fee that would have
been payable, but for this subregulation, as part of an application under subsection
22E(3) of the Act relating to a medicine that is a designated orphan drug; (c) a fee
that would have been payable, but for this subregulation, as part of the registration
of a designated orphan drug; (d) a fee that would have been payable, but for this
subregulation, for applying for a therapeutic goods (priority applicant) determination
in relation to a medicine that is a designated orphan drug.” (Australia)
Sponsor/applicant reimbursement
“There is a special fund (part of the Croatian Health Insurance Fund [CHIF]) for orphan
drugs.. Orphan drugs included in the essential list of drugs of the CHIF are
completely reimbursed, while those included in the additional list are partially
reimbursed.” (Croatia)
continued on next page




Quotations to illustrate the themes
Incentives that encourage
research and development
(44 of 92, 47.8%)
Patent protection/market exclusivity/monopolization
“SEC. 527. (a) Except as provided in subsection (b), if the Secretary- (1) approves
an application filed pursuant to section 505(b), or (2) issues a license under section
351 of the Public Health Service Act for a drug designated under section 526 for
a rare disease or condition and for which a United States Letter of Patent may not
be issued, the Secretary may not approve another application under section 505(b)
or issue another license under section 351 of the Public Health Service Act for such
drug for such disease or condition for a person who is not the holder of such approved
application or of such license until the expiration of seven years from the date of the
approval of the approved application or the issuance of the license. Section 505(c)(2)
does not apply to the refusal to approve an application under the preceding
sentence.” (United States)
Funding for research/development/clinical trials
“SEC. 5. (a) The Secretary may make grants to and enter into contracts with public
and private entities and individuals to assist in defraying the costs of qualified
clinical testing expenses incurred in connection with the development of drugs
for rare diseases and conditions.” (United States)
Scientific advice/consultation
“There are particular challenges associated with designing and conducting trials
in populations with rare diseases. We encourage sponsors to request regulatory
advice from Health Canada before filing their applications. This advice can take a
few different forms depending on the nature of the question. In some cases a
teleconference or email is sufficient. In other cases an in-person meeting may be
appropriate for a more detailed discussion.” (Canada)
CDSCO indicates Central Drugs Standard Control Organisation; DOH, Department of Health; MRP, maximum retail price; NICE, National Institute for Health and Care
Excellence; NPRA, National Pharmaceutical Regulatory Agency; RDTWG, Rare Diseases Technical Working Group.
HEALTH POLICY ANALYSIS 1587of orphan drug trials was identified from European Union
member-states and 6 other countries/areas.
Incentives to encourage the market availability of orphan drugs
were also identified. China offers tax reductions to reduce value-
added tax during the purchasing process of orphan drugs. Pa-
tients with rare diseases are able to obtain drugs free or at low
prices from government or nongovernment organization subsidies
in Colombia and Peru. In Canada and China, orphan drugs can be
imported through the Special Access Programme or pathways for
orphan drugs that are “highly urgently needed in clinical care,”
respectively, which enables sales of drugs that would not other-
wise be sold or distributed in the country. Similarly, in the
Philippines, named-patient programs allow the importation of
orphan drugs via a compassionate special permit before product
registration. European Union member-states and Taiwan have
policies that assist patients in accessing cross-border healthcare.
Price regulation was the least common theme of all identified
ODPs. Various modes of price regulation such as maximum retail
price or price ceiling and price negotiation were identified. In
Bahrain, ODP mechanisms followed that of either innovator drugs
or generic drugs depending on the novelty of the active ingre-
dient. In Austria, orphan drugs are regulated to ensure that the
maximum ex-factory price would not exceed the European Union
average price. Similarly, in Pakistan orphan drugs are exempt from
the maximum price increase (8% per annum of the existing
approved maximum retail price of the respective drug) fixed by
the government. Prices in other countries such as Japan, Austria,
Germany, and Belgium are determined from negotiation between
governmental agencies and pharmaceutical companies.Discussion
Our study presents an overview of global ODP from 194 WHO
member countries and 6 nonmember areas. This includescountries/areas that were not examined previously, especially
those that are non–English speaking and non–high income.11-13
Compared with the 2015 review,11 our findings illustrate major
differences in ODP globally. Ninety-two countries/areas with an
ODP were identified, with a notable increase in ODP establishment
in non-high-income countries/areas. In particular, the world’s top
2 populous countries, China and India, recently established an
ODP. Our findings demonstrate disparities in ODP establishment
and ODP scope by geographical distribution and country/area in-
come level. This underscores the unmet needs in orphan drug
access caused by a lack of an ODP establishment or gaps in policy
scope. Before this review, the global ODP landscape lacked clarity;
therefore, the additional knowledge from countries/areas with
similar cultural, economic, health, and political realities will be
beneficial to policy makers. This will support proposals to improve
the current ODP, or lack thereof, in their own jurisdiction. Simi-
larly, this will help patient organizations to advocate for achiev-
able and realistic ODP changes based on experiences of countries/
areas with similar backgrounds. Finally, this provides a foundation
for future global-scale ODP research, such as cost-effectiveness,
quality improvement, and participatory action studies, that will
be inclusive of countries/areas whose ODP establishment is recent.
Because each country/area’s health system operates under unique
local setting, cross-comparisons of ODP should not be made
without considering underlying cultural, economic, health, and
political factors. Moreover, although commonly applied to rare
diseases, orphan drug designation may also be granted to me-
dicinal products for nonrare diseases with limited treatment op-
tions. For instance, alectinib and ceritinib were approved for
orphan drug status in the United States to treat ALK1 non-small
cell lung cancer, an orphan subset of a nonrare condition.24
Thus, comprehensive contextual understanding must be sought
when interpreting the policy content of each country/area.
Characterized by small patient populations, the free-market
competition of orphan drugs is inherently distorted. Other
Figure 3. Orphan drug policy scope, by income level.
HIC indicates high-income countries; LIC, low-income countries; LMIC, lower-middle income countries; UMIC, upper-middle-income countries.
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HEALTH POLICY ANALYSIS 1589factors contributing to orphan drug market failures include
monopolization, steep research and developmental costs, asym-
metrical knowledge on rare diseases, and inelasticity of patient
demands owing to life-threatening consequences in the absence
of timely drug access.25,26 A robust ODP is critical to correct these
market failures that render conventional regulatory mechanisms
ineffective. Even with existing ODP frameworks, within-
framework policy gaps might lead to unintended perverse ef-
fects when availability and affordability of orphan drugs are not
matched. Although policy content may vary according to local
circumstances, holistic ODP covering different themes should be
in place to outline the regulatory standards that each jurisdiction
is obliged to achieve to ensure fair treatment access for patients
with rare diseases. According to our findings, ODPs from high-
income countries/areas generally attain a wide scope on all pol-
icy themes except for price regulation. This partially explains the
perpetual rise in orphan drug prices. Meanwhile, in non–high-
income countries/areas, incentives that encourage research and
development, incentives that encourage market availability, and
price regulation were underrepresented. Driven by a lack of
attractive benefits, pharmaceutical companies may be less moti-
vated to research and develop orphan drugs, which may deter
market entrants owing to reduced potential return on investment.
This could explain the lack of availability of orphan drugs in non-
high-income countries/areas. Indeed, Picavet et al27 found that
sales and volume uptake of orphan drugs were greater in EU
countries with higher gross domestic product, while Szegedi
et al28 found a greater absolute expenditure and proportion of
gross domestic product allocated to orphan drugs. Orphan drug
availability was low in non-high-income European Union coun-
tries, where budget confinement could exclude non-cost-effective
medications.27,29 Despite differences in country income, external
price referencing systems gave rise to similar drug prices in both
high- and low-income countries, making them less affordable in
low-income countries on account of their ability to pay.28,30 As
such, orphan drug access is more commonly observed in higher-
income countries owing to clearer reimbursement frameworks,
affordable population risk-sharing, and a more favorable
maximum negotiated price.29
To ensure orphan drug availability and affordability, price
negotiation is a common strategy practiced by high-income coun-
tries/areas to moderate changes in equilibrium price and quantity.
In particular, Germany relies on a mandatory price negotiation
mechanism that subjects orphan drugs to cost-benefit analyses.
Nevertheless, such governmental-industry negotiation is often
criticizedas a “blackbox” thatoverlooks patient involvementwhere
transparent consensus among patients, practitioners, and health
technology assessment bodies are vital.31,32 In Belgium, marketing
authorization applicants/holders may negotiate a managed entry
agreement (MEA) if the final decision on the previous drug reim-
bursement requestwas negative orwas notmadewithin the period
specified by the law.33 MEAs are contractual agreements between
marketing authorization holders and payers when price and reim-
bursement cannot be decisively concluded owing to uncertainties
in the clinical effectiveness and budgetary impact of the drug.34
Currently, mechanisms such as various forms of MEAs, pay-for-
performance, risk-sharing models, and patient access schemes
with conditions for medication-use monitoring, outcome mea-
surements, and real-world data collection are being tested.35 To
accommodate the dynamic nature of orphan drug developmental
life cycles, adaptive pricingmechanisms should be adopted. Pricing
should be iterative based on the strength of efficacy and safety ev-
idence, and ranges of indications through indication value-based or
multiple-indication pricing.31 As such, orphan drug prices can be
readjusted based on the updated efficacy and safety evidence orwhen approved for a wider range of indications such as nonrare
diseases in the future.31 In The Netherlands, a conditional reim-
bursement trajectorywas introduced requiring authorized drugs to
be reevaluated every 4 years.
Alternative policy frameworks that may facilitate orphan drug
access exist; however, their nonspecificity place them outside the
scope of this review. First, patients may continue to access orphan
drugs via non-orphan-drug-specific policies and ad hoc requests.
Some countries/areas have pathways that facilitate access to
broader special drugs, including orphan drugs. Examples include
Armenia (low demand but vital drugs), Brunei (drugs intended to
treat serious or life-threatening conditions), Hong Kong and
Turkey (named-patient basis), and Saudi Arabia (drugs addressed
unmet medical needs). Yet, patients with rare diseases and foreign
orphan drug suppliers may be required to navigate myriad time-
consuming procedures to access orphan drugs if pathways are
non-orphan drug–specific or if requests are processed on an ad
hoc basis. Secondly, where resources are scarce, orphan drugs are
unlikely to be accessible without appropriate policies. To facilitate
timely patient access to orphan drugs, countries/areas may
consider leveraging the WHO prequalification approval and par-
allel or twinned approval with the help of foreign competent
authorities to uphold regulatory standards.36 Countries/areas may
subsidize patients’ cross-border health treatment if the required
treatment and expertise present too many barriers to import.
Third, 7 countries/areas in our studies had no identifiable DRAs.
Stepwise efforts should be made to assist these countries in
setting up and strengthening the DRA. Regional ODP frameworks
in the European Union and Central America are useful examples of
how neighboring countries with similar rare disease epidemiology
and patient needs can converge regulatory efforts for orphan
drugs. Existing frameworks can be extended while designing
specifications that incorporate their unique cultural, economic,
health, and political backgrounds.
The methodology of our review was designed to overcome the
limitations faced by previous reviews. First, previous reviews were
limited to a selection of countries determined by authors based on
geographical and socioeconomic diversity, and confined to publi-
cation and reporting biases.11-13 In this study, we sought to obtain
information from all countries by meticulously searching for evi-
dence from direct governmental sources and systematic academic
literature searches. Second, previous studies were limited to En-
glish publications, discounting the representativeness of the
qualitative synthesis, particularly in many low- and middle-
income countries/areas. To maximize the completeness of our
narrative synthesis, non-English documents were translated to
identify policies. One limitation of our study is that this review
only examined ODP in 6 non-WHO member areas. Other non-
WHO member-countries/areas with DRAs may be missed. Addi-
tionally, state- or province-level governmental evidence was not
assessed, therefore within-country variations in policy develop-
ment were not considered. Lastly, 33.1% (54 of 163) of drug
regulation documents required translation to English, which could
potentially incur minor inaccuracies during interpretation.
Collaboration with experts from various countries and interna-
tional organizations has helped to mitigate the last limitation.
Current ODP implementation is limited by a lack of robust
evidence. Of note, landmark trials for orphan drugs are subject to
single-arm, open-label study design with small sample sizes and
inadequate long-term outcome assessment.37 Uncertainties
remain in the effectiveness and safety of orphan drugs in real-
world settings. Therefore, future research that aims to establish
rare disease registries, unbiased from industry influence, is
important to collect reliable longitudinal data for the post-
marketing effectiveness and safety evaluation of orphan drugs.38
1590 VALUE IN HEALTH DECEMBER 2020Innovative solutions such as mining big data for adverse event
information and the role of social media in pharmacovigilance
should be explored.39 Meanwhile, the impact of established ODP
on patient access to treatment and patient outcomes requires
comprehensive, rigorous evaluation.
Conclusions
While observing the global growth of ODP establishment, drug
authorities should be prepared to develop or refine current pol-
icies to optimize patient access to orphan drugs. In particular,
policy improvements in the thematic areas of price regulation,
incentives that encourage market availability, and incentives that
encourage research and development are recommended to ensure
affordability for payers with sufficient returns for manufacturers.
Case practices and the results of policy implementation from
countries/areas with ODPs will benefit those seeking to develop
their own policies.
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